NCT00321308 - Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG

pemetrexed

500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity

DRUG

pemetrexed + PF-3512676

pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity

Trial Locations (20)

10126

Pfizer Investigational Site, Torino

13126

Pfizer Investigational Site, Oswego

13210

Pfizer Investigational Site, Syracuse

13421

Pfizer Investigational Site, Oneida

22927

Pfizer Investigational Site, Großhansdorf

34655

Pfizer Investigational Site, New Port Richey

34667

Pfizer Investigational Site, Hudson

43560

Pfizer Investigational Site, Sylvania

68167

Pfizer Investigational Site, Mannheim

72703

Pfizer Investigational Site, Fayetteville

72712

Pfizer Investigational Site, Bentonville

85340

Pfizer Investigational Site, Litchfield Park

85351

Pfizer Investigational Site, Sun City

89109

Pfizer Investigational Site, Seattle

98195

Pfizer Investigational Site, Seattle

07430

Pfizer Investigational Site, Mahwah

07432

Pfizer Investigational Site, Midland Park

07652

Pfizer Investigational Site, Paramus

07675

Pfizer Investigational Site, Westwood

13210-2306

Pfizer Investigational Site, Syracuse